OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.

A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores potential solutions to these challenges. Three key topics are explored: uncertainty, discounting, and health outcomes and value. A series of recommendations are proposed.

The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better tuberculosis treatment. Our market-focused approach puts Brazil, Russia, India, China, and South Africa (the BRICS) governments in the driver’s seat—empowering them to send a powerful signal to private-sector pharmaceutical companies about the innovation they value and at the kind of price they are willing to consider.

OHE Lunchtime Seminar with Mariana Mazzucato on Re-imagining Health Innovation to Deliver Public Value. 28 September 2018 12:00-2:00pm.

This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.

A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.

To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?

What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?

OHE, in collaboration with RAND Europe and King’s College, has been awarded a research grant from Cancer Research UK exploring outcome-based payments.

In this paper, Sir Geoffrey Owen and Dr Michael Hopkins discuss ‘The UK Biotech Sector and Brexit: Past Performance and Future Prospects’.


Subscribe to RSS - Innovation